Behairy El-Sayed Behairy1, Magdy Anwar Saber1, Rasha Elsayed Hassan2, Samira Abd-Elwahab Abd-Elaziz1, Haidy Mohammed Zakaria3* and Gihan Ahmed Sobhy1
1Department of Pediatric Hepatology, Gastroenterology and Nutrition, National Liver Institute, Menoufia University, Egypt
2Pediatric Department, Temi Alamdid Hospital, Ministry of Health, Egypt
3Pediatric Department, Quesna Central Hospital, Ministry of Health, Menoufia, Egypt
*Corresponding Author: Haidy Mohammed Zakaria, Pediatric Department, Quesna Central Hospital, Ministry of Health, Menoufia, Egypt.
Received: August 24, 2020; Published: September 16, 2020
Introduction: Hyperbilirubinemia is a common benign problem in neonates, however in some circumstances; it may cause bilirubin induced neurological dysfunction. Although phototherapy remains the mainstay of treatment for neonatal jaundice, it has some side effects.
Aim: The aim of this study was to assess the additive effect of Ursodeoxycholic Acid (UDCA) in reducing indirect hyperbilirubinemia in neonates under phototherapy.
Patients and Methods: This randomized controlled study was performed on 100 newborn with indirect hyperbilirubinemia divided into two groups. Group A: included 50 neonates, received Ursodeoxycholic Acid orally in addition to phototherapy. Group B: included 50 neonates, received phototherapy only. All patients were subjected to detailed history taking, thorough clinical examination and laboratory investigations. Total serum bilirubin (TSB) and direct bilirubin were measured on admission and followed up every 12 hours (h) till serum bilirubin became below 10 mg/dl.
Results: The sex, mean age and weight, onset of jaundice and total serum bilirubin at the time of admission were comparable in both groups (P > 0.05). The mean TSB measured at 12h, 24h, 36h and 48h of phototherapy in group A was 13.82 ± 1.11, 11.94 ± 1.60, 10.66 ± 1.52, 9.48 ± 1.33 mg/dl respectively and in group B was 15.15 ± 1.41 at 12h, 13.70 ± 1.25 at 24h, 12.49 ± 1.25 at 36h, 11.47 ± 1.13 at 48h. The TSB levels were significantly lower in the group who received UDCA and phototherapy (P < 0.05). The mean duration under phototherapy till reaching TSB < 10 mg/dl in group A (42.96h) were significantly lower than that in group B (71.52 h) (P < 0.0001).
Conclusion: UDCA is considered an effective and safe complementary therapeutic adjuvant in neonatal indirect hyperbilirubinemia.
Keywords: Hyperbilirubinemia; Jaundice; Neonates; Phototherapy; Ursodeoxycholic Acid
Citation: Haidy Mohammed Zakaria., et al. “Role of Ursodeoxycholic Acid in Lowering Indirect Hyperbilirubinemia in Neonates Under Phototherapy". Acta Scientific Gastrointestinal Disorders 3.10 (2020): 07-11.
Copyright: © 2020 Haidy Mohammed Zakaria., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.